Spark Biomedical Appoints Anja Krammer as CEO to Drive Bioelectronic Medicine Platform Forward
核心洞察
Spark Biomedical (搜索), a Dallas-based bioelectronic medicine company, has appointed Anja Krammer (搜索) as Chief Executive Officer to accelerate clinical validation and commercial growth.
The company has developed proprietary neuromodulation technology targeting vagus and trigeminal cranial nerves for applications in mental health, women's health, hemostasis, and bleeding disorders (搜索).
Krammer brings extensive experience scaling healthcare and medical technology companies across cardiac, dermatology, and women's health therapies.
Dallas-based Spark Biomedical (搜索) announced the appointment of Anja Krammer (搜索) as Chief Executive Officer on May 4, 2026, marking a strategic leadership transition as the bioelectronic medicine company advances its neuromodulation platform toward clinical validation and commercial expansion.
Krammer brings proven expertise in scaling healthcare and medical technology companies, with a track record of translating breakthrough innovations into commercially successful products across clinical and consumer markets. She has served on public and private company boards and held senior executive roles driving clinical and commercialization initiatives in cardiac, dermatology, and women's health therapies.
Proprietary Neuromodulation Technology Platform
Spark Biomedical (搜索) has developed proprietary neuromodulation technology targeting the vagus and trigeminal cranial nerves, with applications spanning mental health, women's health, hemostasis, bleeding disorders (搜索), and broader wellness indications. The company's patented technology has been adopted by leading institutions engaged in the application of neurostimulation for health improvement.
The company is advancing both regulated clinical products and consumer-facing solutions built on the same scientific foundation, positioning itself in the emerging bioelectronic medicine market.
Strategic Growth Focus
"Spark Biomedical (搜索) is changing many lives for the better through its novel platform," said Matt Harrison (搜索), Chair of the Board of Directors. "Anja's leadership, experience, and scientific rigor will take the company to new and exciting heights allowing it to serve so many more that will benefit from Spark's therapies. The Board is excited to partner with Anja as she leads Spark through its next phase of clinical validation, regulatory advancement, and global commercialization."
Krammer will prioritize accelerated growth by advancing Spark's clinical programs and regulatory pathways, expanding commercial capabilities across healthcare and consumer channels, strengthening strategic partnerships, and driving sustainable, profitable revenue expansion.
Leadership Transition and Neural Tourniquet Development
"I am honored to join Spark Biomedical (搜索) as CEO," said Anja Krammer (搜索). "Our innovative technology platform and exceptional team position us to accelerate growth, deliver strong stakeholder value, and lead the bioelectronic medicine market to improve patient health. I look forward to building on our foundation to achieve superior clinical outcomes and commercial success."
Krammer, who assumed her role as CEO on May 4th, will also serve on Spark's Board of Directors. Outgoing CEO and cofounder Daniel Powell (搜索) will now focus on one of Spark's latest products, the "Neural Tourniquet (搜索)," which stimulates the body's clotting response, leading it through FDA approval and commercialization.